Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elad Sharon

Showing results (91-100 of 191) with videos related to

Pageof 20
Sort By:
Cancer|February 15, 2024
SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancerSandip P Patel, Elizabeth Guadarrama, Young Kwang Chae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2024
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial CancerRandy F Sweis, Gurkamal S Chatta, Rohit K Jain, et al.
JNCI Cancer Spectrum|February 8, 2025
The use of large language models to enhance cancer clinical trial educational materialsMingye Gao, Aman Varshney, Shan Chen, et al.
Haematologica|July 18, 2024
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphomaTamer Othman, Paul Frankel, Pamela Allen, et al.
Journal for Immunotherapy of Cancer|September 29, 2024
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumorsYoung Kwang Chae, Megan Othus, Sandip Patel, et al.
Journal for Immunotherapy of Cancer|March 31, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminologyJarushka Naidoo, Catherine Murphy, Michael B Atkins, et al.
Journal for Immunotherapy of Cancer|November 18, 2021
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational studyFangwen Zou, David Faleck, Anusha Thomas, et al.
Therapeutic Advances in Medical Oncology|November 25, 2024
Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)Young Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Journal for Immunotherapy of Cancer|October 2, 2020
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancerClaire F Friedman, Alexandra Snyder Charen, Qin Zhou, et al.
World Journal of Oncology|January 21, 2022
Advances in Oncology in US and Japan: Focusing on Cancer and Infectious DiseasesHiroto Nakano, Takuto Miyamoto, Yelena Y Janjigian, et al.
Pageof 20

Showing results (91-100 of 191) with videos related to

Sort By:
Pageof 20
Cancer|February 15, 2024
SWOG 1609 cohort 48: anti-CTLA-4 and anti-PD-1 for advanced gallbladder cancerSandip P Patel, Elizabeth Guadarrama, Young Kwang Chae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 22, 2024
A Phase II Open-Label, Randomized Clinical Trial of Atezolizumab with or without Human Recombinant IL-7 (CYT107) in Advanced Urothelial CancerRandy F Sweis, Gurkamal S Chatta, Rohit K Jain, et al.
JNCI Cancer Spectrum|February 8, 2025
The use of large language models to enhance cancer clinical trial educational materialsMingye Gao, Aman Varshney, Shan Chen, et al.
Haematologica|July 18, 2024
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphomaTamer Othman, Paul Frankel, Pamela Allen, et al.
Journal for Immunotherapy of Cancer|September 29, 2024
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumorsYoung Kwang Chae, Megan Othus, Sandip Patel, et al.
Journal for Immunotherapy of Cancer|March 31, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminologyJarushka Naidoo, Catherine Murphy, Michael B Atkins, et al.
Journal for Immunotherapy of Cancer|November 18, 2021
Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational studyFangwen Zou, David Faleck, Anusha Thomas, et al.
Therapeutic Advances in Medical Oncology|November 25, 2024
Phase II trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors SWOG/NCI experience: invasive mucinous or non-mucinous lepidic adenocarcinoma of the lung (formerly bronchioloalveolar carcinoma)Young Kwang Chae, Megan Othus, Sandip Pravin Patel, et al.
Journal for Immunotherapy of Cancer|October 2, 2020
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancerClaire F Friedman, Alexandra Snyder Charen, Qin Zhou, et al.
World Journal of Oncology|January 21, 2022
Advances in Oncology in US and Japan: Focusing on Cancer and Infectious DiseasesHiroto Nakano, Takuto Miyamoto, Yelena Y Janjigian, et al.
Pageof 20